1-piperazin-1-yltetradecan-1-one | 147642-56-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-piperazin-1-yltetradecan-1-one
• 英文别名: 1-tetradecanoylpiperazine
• CAS: 147642-56-6
• 化学式: C₁₈H₃₆N₂O
• 分子量: 296.497
• InChiKey: FUGOICILJFCMDR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  21
• 可旋转键数：
  12
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-piperazin-1-yltetradecan-1-one 在 lithium aluminium tetrahydride 、 硫酸 作用下， 以 四氢呋喃 为溶剂， 生成 1-十四烷基哌嗪
  参考文献：
  名称：

  长烷基链酰胺，胺及其衍生物对犬round虫幼虫的杀线虫活性。

  摘要：

  检查了具有长烷基链的酰胺和胺对犬round虫第二阶段幼虫的杀线虫活性。在氮上具有较小取代基的长链酰基酰胺显示出更强的活性，环状胺酰胺的活性强于无环酰胺。在一系列同源酰胺中，活性取决于烷基链长：在最佳链长处达到最大值，而在较短和较长的同系物中均降低。通过使用双线性模型分析了同系物的活性与疏水性之间的关系。对于所有中性酰胺，提供最大活性的化合物的疏水性均相似，但分子中具有额外胺基的酰胺具有不同的值。具有长烷基链的叔胺及其盐也具有与相应酰胺相当的杀线虫活性。这些盐以低于其临界胶束浓度的浓度杀死幼虫，表明它们表现为杀线虫作用的单个分子。

  DOI：

  10.1248/cpb.40.3234
• 作为产物：
  描述：

  肉豆蔻酸 在 N-甲基吗啉 、 三氟乙酸 、 氯甲酸异丁酯 作用下， 以 二氯甲烷 为溶剂， 反应 21.5h， 生成 1-piperazin-1-yltetradecan-1-one
  参考文献：
  名称：

  [EN] SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS
  [FR] AGENTS THÉRAPEUTIQUES ANTICANCÉREUX DE CDK4/6 SÉLECTIFS

  摘要：

  本公开描述了一类选择性和有效的CDK 4/6抑制剂，即使在低浓度下也显示出对癌症生长的有利抑制作用。这类抗癌CDK 4/6抑制剂是具有脂肪酸基团的化学式1A的取代吡咯吡嘧啶化合物。这些化合物可用作抗癌疗法的药物化合物，并可用于癌症的治疗、预防和/或改善。

  公开号：

  WO2021124106A1

文献信息

• Synthesis and anticancer evaluation of new lipophilic 1,2,4 and 1,3,4-oxadiazoles
  作者：Wiliam Caneschi、Karine Braga Enes、Camille Carvalho de Mendonça、Fábio de Souza Fernandes、Fabio Balbino Miguel、Jefferson da Silva Martins、Mireille Le Hyaric、Roberto Rosas Pinho、Lucas Mattos Duarte、Marcone Augusto Leal de Oliveira、Hélio F. Dos Santos、Miriam Teresa Paz Lopes、Dalton Dittz、Heveline Silva、Mara Rubia Costa Couri

  DOI：10.1016/j.ejmech.2019.01.001

  日期：2019.3

  A series of1,2,4- and 1,3,4-oxadiazole derivatives were synthesized and evaluated for their anticancer activity. Halogenated 1,2,4-oxadiazoles were obtained from benzonitrile and coupled either lipophilic amines or with aminoalcohols. Lipophilic 1,3,4-oxadiazole derivatives were obtained through the Mannich reactions between 5-(aryl)-1,3,4-oxadiazole-2-thiol and alkylated or acylated amines. The in vitro

  合成了一系列1,2,4-和1,3,4-恶二唑衍生物，并评估了其抗癌活性。卤代的1,2,4-恶二唑从苄腈获得，并与亲脂性胺或氨基醇偶联。亲脂性1,3,4-恶二唑衍生物是通过5-（芳基）-1,3,4-恶二唑-2-硫醇与烷基化或酰化胺之间的曼尼希反应获得的。在体外的细胞毒性效应对4T1-乳腺癌评价和CT26 -结肠癌细胞。1,3,4-恶二唑与具有10-14个碳链部分的烷基化哌嗪偶联的IC 50为最佳 对于4T1细胞系，其值范围为1.6至3.55μM，对于CT26.WT细胞系，其值范围为1.6至3.9μM，选择性指数最高为19。最有效的化合物采用AnnexinV和PI染色进行了研究，可作为细胞凋亡诱导的指示。
• Design of new potent and selective secretory phospholipase A2 inhibitors. 6-Synthesis, structure–activity relationships and molecular modelling of 1-substituted-4-[4,5-dihydro-1,2,4-(4H)-oxadiazol-5-one-3-yl(methyl)]-functionalized aryl piperazin/one/dione derivatives
  作者：Nadia Meddad-Belhabich、Darina Aoun、Atimé Djimdé、Catherine Redeuilh、Georges Dive、France Massicot、François Chau、Françoise Heymans、Aazdine Lamouri

  DOI：10.1016/j.bmc.2010.03.049

  日期：2010.5

  The group IIA human non-pancreatic secretory phospholipase A(2) (hnp-sPLA(2)) is one of the enzymes implied in the inflammatory process. In the course of our work on inhibitors of this enzyme we investigated the influence of rigidity of the piperazine region on the biological activity. Several modifications were explored. Various linkers, such as amide, urea, carbamate, or alkoxyphenyl were inserted between the piperazine and the lipophilic chain. Also, modification of the piperazine core to incorporate carbonyl groups was studied. In an in vitro fluorimetric assay using the human GIIA (HPLA(2)) and porcine pancreatic GIB enzymes, compound 60a (Y = phenoxy, R = C18H37, Z= CH2) had the optimal activity with an IC50 = 30 nM on HPLA(2). By means of molecular modelling we attempted to get informations towards comprehension of differences in activity. (C) 2010 Elsevier Ltd. All rights reserved.
• [EN] SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS<br/>[FR] AGENTS THÉRAPEUTIQUES ANTICANCÉREUX INHIBITEURS SÉLECTIFS DE CDK 4/6
  申请人：LUNELLA BIOTECH INC

  公开号：WO2021124104A1

  公开（公告）日：2021-06-24

  The disclosure describes selective and potent CDK 4/6 inhibitors that show advantageous inhibition of cancer growth, even at low concentrations. A class of the CDK 4/6 inhibitors relates to substituted pyridopyrimidines compounds having a fatty acid moiety, and are namely derivatives of Palbociclib of general formula [2A], wherein R1 is hydrogen, aryl, alkyl, alkoxy, cycloalkyl, or heterocyclyl; R2 is hydrogen, halogen, alkyl, acyl, cycloalkyl, alkoxy, alkoxy alkyl, haloalkyl, hydroxy alkyl, alkenyl, alkynyl, nitrile, or nitro; R3 is hydrogen, halogen, alkyl, haloalkyl, hydroxy alkyl, or cycloalkyl; and n is an integer from 9 to 20. These compounds may be used as pharmaceutical compounds for anti-cancer therapies, and are useful for the treatment, prevention and/or amelioration of cancer.